[1]
|
Trosset, J.Y. and Carbonell, P. (2015) Synthetic Biology for Pharmaceutical Drug Discovery. Drug Design, Development, and Therapy, 9, 6285-6302.
https://doi.org/10.2147/DDDT.S58049
|
[2]
|
Duelen, R., Corvelyn, M., Tortorella, I., Leonardi, L., Chai, Y.C. and Sampaolesi, M. (2019) Medicinal Biotechnology for Disease Modeling, Clinical Therapy, and Drug Discovery and Development. In: Matei, F. and Zirra, D., Eds., Introduction to Biotech Entrepreneurship: From Idea to Business, Springer, Berlin, 89-128.
https://doi.org/10.1007/978-3-030-22141-6_5
|
[3]
|
Ho, R.J. (2013) Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes into Drugs. John Wiley & Sons, Hoboken.
https://doi.org/10.1002/9781118660485
|
[4]
|
Miller, H.I. (2013) Biotechnology. In: Maloy, S. and Hughes, K., Eds., Brenner’s Encyclopedia of Genetics, 2nd Edition, Elsevier, Amsterdam, 346-348.
https://doi.org/10.1016/B978-0-12-374984-0.00157-1
|
[5]
|
Gaisser, S. and Nusser, M. (2010) Stellenwert der Biotechnologie in der pharmazeutischen Wirkstoffentwicklung. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen, 104, 732-737. https://doi.org/10.1016/j.zefq.2010.05.001
|
[6]
|
Neagu, M., Albulescu, R. and Tanase, C. (2015) Biotechnology Landscape in Cancer Drug Discovery. Future Science OA, 1, FSO12. https://doi.org/10.4155/fso.15.10
|
[7]
|
Ward, S.J. (2001) Impact of Genomics in Drug Discovery. BioTechniques, 31, 1-2.
https://doi.org/10.2144/01313dd01
|
[8]
|
Kabadi, A., McDonnell, E., Frank, C.L. and Drowley, L. (2020) Applications of Functional Genomics for Drug Discovery. Sage Journals, 25, 823-842.
https://doi.org/10.1177/2472555220902092
|
[9]
|
Peter, H. (2015) How Genome Sequencing Is Aiding Drug Research and Development.
https://www.proclinical.com/blogs/2015-7/genome-sequencing-is-aiding-drug-research-and-development
|
[10]
|
Wang, L., McLeod, H.L. and Weinshilboum, R.M. (2011) Genomics and Drug Response. New England Journal of Medicine, 364, 1144-1153.
https://doi.org/10.1056/NEJMra1010600
|
[11]
|
Lundstrom, K. (2011) Genomics and Drug Discovery. Future Medicinal Chemistry, 3, 1855-1858. https://doi.org/10.4155/fmc.11.140
|
[12]
|
Spreafico, R., Leah, B., Grossse, J., Virgin, H. and Telenti, A. (2020) Advances in Genomics for Drug Development. Genes, 11, 942.
https://doi.org/10.3390/genes11080942
|
[13]
|
Neha, S. and Harikumar, L. (2013) Use of Genomics and Proteomics in Pharmaceutical Drug Discovery and Development: A Review. International Journal of Pharmacy and Pharmaceutical Sciences, 5, 24-28.
|
[14]
|
Bumol, T.F. and Watanabe, A.M. (2001) Genetic Information, Genomic Technologies, and the Future of Drug Discovery. JAMA, 285, 551-555.
https://doi.org/10.1001/jama.285.5.551
|
[15]
|
Zhang, H.M., Nan, Z.R., Hui, G.Q., Liu, X.H. and Sun, Y. (2014) Application of Genomics and Proteomics in Drug Target Discovery. Genetics and Molecular Research: GMR, 13, 198-204. https://doi.org/10.4238/2014.January.10.11
|
[16]
|
Amiri-Dashatan, N., Koushki, M., Abbaszadeh, H.A., Rostami-Nejad, M. and Rezaei-Tavirani, M. (2018) Proteomics Applications in Health: Biomarker and Drug Discovery and Food Industry. Iranian Journal of Pharmaceutical Research: IJPR, 17, 1523.
|
[17]
|
Frantzi, M., Latosinska, A. and Mischak, H. (2019) Proteomics in Drug Development: The Dawn of a New Era? Proteomics-Clinical Applications, 13, Article ID: 1800087. https://doi.org/10.1002/prca.201800087
|
[18]
|
Jhanker, Y., Kadir, M., Khan, R. and Hasan, R. (2012) Proteomics in Drug Discovery, Journal of Applied Pharmaceutical Science, 2, 1-12.
https://doi.org/10.7324/JAPS.2012.2801
|
[19]
|
Hewick, R.M., Lu, Z. and Wang, J.H. (2003) Proteomics in Drug Discovery. In: Advances in Protein Chemistry, Vol. 65, Elsevier, Amsterdam, 309-342.
https://doi.org/10.1016/S0065-3233(03)01024-6
|
[20]
|
Walgran, J.L. and Thompson, D.C. (2004) Application of Proteomic Technologies in the Drug Development Process. Toxicology Letters, 149, 377-385.
https://doi.org/10.1016/j.toxlet.2003.12.047
|
[21]
|
Gromova, M., Vaggelas, A., Dallmann, G. and Seimetz, D. (2020) Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape. Biomarker Insights, 15. https://doi.org/10.1177/1177271920974652
|
[22]
|
Schomaker, S., Ramaiah, S., Khan, N. and Burkhardt, J. (2019) Safety Biomarker Applications in Drug Development. The Journal of Toxicological Sciences, 44, 225-235. https://doi.org/10.2131/jts.44.225
|
[23]
|
Shendure, J. and Ji, H. (2008) Next-Generation DNA Sequencing. Nature Biotechnology, 26, 1135-1145. https://doi.org/10.1038/nbt1486
|
[24]
|
McCarthy, M.I. and Hirschhorn, J.N. (2008) Genome-Wide Association Studies: Potential Next Steps on a Genetic Journey. Human Molecular Genetics, 17, R156-R165. https://doi.org/10.1093/hmg/ddn289
|
[25]
|
Altelaar, A.F., Munoz, J. and Heck, A.J. (2013) Next-Generation Proteomics: Towards an Integrative View of Proteome Dynamics. Nature Reviews Genetics, 14, 35-48. https://doi.org/10.1038/nrg3356
|
[26]
|
Aebersold, R. and Mann, M. (2016) Mass-Spectrometric Exploration of Proteome Structure and Function. Nature, 537, 347-355. https://doi.org/10.1038/nature19949
|
[27]
|
Aksu, B., Sezer, A.D., Yegen, G. and Kusçu, L. (2016) QbD Implementation in Biotechnological Product Development Studies. In: Chen, T.S. and Chai, S.C., Eds., Special Topics in Drug Discovery, IntechOpen, London, 133-155.
https://doi.org/10.5772/66296
|
[28]
|
Nayak, A.K., Ahmed, S.A., Beg, S., Tabish, M. and Hasnain, M.S. (2019) Application of Quality by Design for the Development of Biopharmaceuticals. In: Beg, S. and Hasnain, M.S., Eds., Pharmaceutical Quality by Design, Academic Press, Cambridge, 399-411. https://doi.org/10.1016/B978-0-12-815799-2.00019-8
|
[29]
|
Rathore, A.S. and Winkle, H. (2009) Quality by Design for Biopharmaceuticals. Nature Biotechnology, 27, 26-34. https://doi.org/10.1038/nbt0109-26
|
[30]
|
Varu, R.K. and Khanna, A. (2010) Opportunities and Challenges to Implementing the Quality by Design Approach in Generic Drug Development. Journal of Generic Medicines, 7, 60-73. https://doi.org/10.1057/jgm.2009.37
|
[31]
|
Rathore, A.S. (2009) Roadmap for Implementation of Quality by Design (QbD) for Biotechnology Products. Trends in Biotechnology, 27, 546-553.
https://doi.org/10.1016/j.tibtech.2009.06.006
|
[32]
|
Tomba, E., Facco, P., Bezzo, F. and Barolo, M. (2013) Latent Variable Modeling to Assist the Implementation of Quality-by-Design Paradigms in Pharmaceutical Development and Manufacturing: A Review. International Journal of Pharmaceutics, 457, 283-297. https://doi.org/10.1016/j.ijpharm.2013.08.074
|
[33]
|
Yu, L.X. (2008) Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control. Pharmaceutical Research, 25, 781-791.
https://doi.org/10.1007/s11095-007-9511-1
|
[34]
|
Yu, L.X., Amidon, G., Khan, M.A., Hoag, S.W., Polli, J., Raju, G.K. and Woodcock, J. (2014) Understanding Pharmaceutical Quality by Design. The AAPS Journal, 16, 771-783. https://doi.org/10.1208/s12248-014-9598-3
|
[35]
|
Thompson, R.A., Isin, E.M., Li, Y., Weaver, R., Weidolf, L., Wilson, I. and Kenna, J.G. (2011) Risk Assessment and Mitigation Strategies for Reactive Metabolites in Drug Discovery and Development. Chemical-Biological Interactions, 192, 65-71.
https://doi.org/10.1016/j.cbi.2010.11.002
|
[36]
|
Zhang, X., Lionberger, R.A., Davit, B.M. and Yu, L.X. (2011) Utility of Physiologically Based Absorption Modeling in Implementing Quality by Design in Drug Development. The AAPS Journal, 13, 59-71.
https://doi.org/10.1208/s12248-010-9250-9
|
[37]
|
Hu, L., Fawcett, J.P. and Gu, J. (2012) Protein Target Discovery of Drug and Its Reactive Intermediate Metabolite by Using Proteomic Strategy. Acta Pharmaceutica Sinica B, 2, 126-136. https://doi.org/10.1016/j.apsb.2012.02.001
|
[38]
|
Dimitrov, D.S. (2012) Therapeutic Proteins. In: Voynov, V. and Caravella, J.A., Eds., Therapeutic Proteins Methods and Protocols, Vol. 899, Springer, Berlin, 1-26.
https://doi.org/10.1007/978-1-61779-921-1_1
|
[39]
|
Zheng, J., Mehl, J., Zhu, Y., Xin, B. and Olah, T. (2014) Application and Challenges in Using LC-MS Assays for Absolute Quantitative Analysis of Therapeutic Proteins in Drug Discovery. Bioanalysis, 6, 859-879. https://doi.org/10.4155/bio.14.36
|
[40]
|
Daub, H., Godl, K., Brehmer, D., Klebl, B. and Müller, G. (2004) Evaluation of Kinase Inhibitor Selectivity by Chemical Proteomics. Assay and Drug Development Technologies, 2, 215-224. https://doi.org/10.1089/154065804323056558
|
[41]
|
Staker, B.L., Buchko, G.W. and Myler, P.J. (2015) Recent Contributions of Structure-Based Drug Design to the Development of Antibacterial Compounds. Current Opinion in Microbiology, 27, 133-138. https://doi.org/10.1016/j.mib.2015.09.003
|
[42]
|
Moellering, R.E. and Cravatt, B.F. (2012) How Chemoproteomics Can Enable Drug Discovery and Development. Chemistry & Biology, 19, 11-22.
https://doi.org/10.1016/j.chembiol.2012.01.001
|
[43]
|
Debouck, C. (2009) Integrating Genomics across Drug Discovery and Development. Toxicology Letters, 186, 9-12. https://doi.org/10.1016/j.toxlet.2008.09.011
|
[44]
|
Bahadduri, P.M., Polli, J.E., Swaan, P.W. and Ekins, S. (2010) Targeting Drug Transporters-Combining in Silico and in Vitro Approaches to Predict in Vivo. In: Yan, Q., Ed., Membrane Transporters in Drug Discovery and Development, Springer, Berlin, 65-103. https://doi.org/10.1007/978-1-60761-700-6_4
|
[45]
|
Gomez-Lechon, M.J., Lahoz, A., Gombau, L., Castell, J.V. and Donato, M.T. (2010) In Vitro Evaluation of Potential Hepatotoxicity Induced by Drugs. Current Pharmaceutical Design, 16, 1963-1977. https://doi.org/10.2174/138161210791208910
|
[46]
|
Vandana, U.K., Rajkumari, J., Singha, L.P., Satish, L., Alavilli, H., Sudheer, P.D. and Pandey, P. (2021) The Endophytic Microbiome as a Hotspot of Synergistic Interactions, with Prospects of Plant Growth Promotion. Biology, 10, Article No. 101.
https://doi.org/10.3390/biology10020101
|
[47]
|
Risueño, I., Valencia, L., Jorcano, J.L. and Velasco, D. (2021) Skin-on-a-Chip Models: General Overview and Future Perspectives. APL Bioengineering, 5, Article ID: 030901. https://doi.org/10.1063/5.0046376
|
[48]
|
Van Vliet, P., Sluijter, J.P., Doevendans, P.A. and Goumans, M.J. (2007) Isolation and Expansion of Resident Cardiac Progenitor Cells. Expert Review of Cardiovascular Therapy, 5, 33-43. https://doi.org/10.1586/14779072.5.1.33
|
[49]
|
Nirmalanandhan, V.S. and Sittampalam, G.S. (2009) Stem Cells in Drug Discovery, Tissue Engineering, and Regenerative Medicine: Emerging Opportunities and Challenges. Journal of Biomolecular Screening, 14, 755-768.
https://doi.org/10.1177/1087057109336591
|
[50]
|
Mimeault, M. and Batra, S.K. (2006) Concise Review: Recent Advances on the Significance of Stem Cells in Tissue Regeneration and Cancer Therapies. Stem Cells, 24, 2319-2345. https://doi.org/10.1634/stemcells.2006-0066
|
[51]
|
Keung, A.J., Kumar, S. and Schaffer, D.V. (2010) Presentation Counts: Microenvironmental Regulation of Stem Cells by Biophysical and Material Cues. Annual Review of Cell and Developmental Biology, 26, 533-556.
https://doi.org/10.1146/annurev-cellbio-100109-104042
|
[52]
|
Augello, A., Kurth, T.B. and De Bari, C. (2010) Mesenchymal Stem Cells: A Perspective from in Vitro Cultures to in Vivo Migration and Niches. European Cells and Materials, 20, e33. https://doi.org/10.22203/eCM.v020a11
|
[53]
|
Hunter, P.J. and Borg, T.K. (2003) Integration from Proteins to Organs: The Physiome Project. Nature Reviews Molecular Cell Biology, 4, 237-243.
https://doi.org/10.1038/nrm1054
|
[54]
|
Noble, D. (2002) Modeling the Heart—From Genes to Cells to the Whole Organ. Science, 295, 1678-1682. https://doi.org/10.1126/science.1069881
|
[55]
|
Bassingthwaighte, J.B. and Vinnakota, K.C. (2004) The Computational Integrated Myocyte: A View into the Virtual Heart. Annals of the New York Academy of Sciences, 1015, 391-404. https://doi.org/10.1196/annals.1302.034
|
[56]
|
Wang, F.Y. and Wong, P.K. (2013) Intelligent Systems and Technology for Integrative and Predictive Medicine: An ACP Approach. ACM Transactions on Intelligent Systems and Technology (TIST), 4, 1-6. https://doi.org/10.1145/2438653.2438667
|
[57]
|
Li, S., Zhang, B. and Zhang, N. (2011) Network Target for Screening Synergistic Drug Combinations with Application to Traditional Chinese Medicine. BMC Systems Biology, 5, 1-13. https://doi.org/10.1186/1752-0509-5-S1-S10
|
[58]
|
Kuhn, M., Campillos, M., Letunic, I., Jensen, L.J. and Bork, P. (2010) A Side Effect Resource to Capture Phenotypic Effects of Drugs. Molecular Systems Biology, 6, 343. https://doi.org/10.1038/msb.2009.98
|
[59]
|
Ekins, S., Williams, A.J., Krasowski, M.D. and Freundlich, J.S. (2011) In Silico Repositioning of Approved Drugs for Rare and Neglected Diseases. Drug Discovery Today, 16, 298-310. https://doi.org/10.1016/j.drudis.2011.02.016
|
[60]
|
Mendrick, D.L. (2011) Transcriptional Profiling to Identify Biomarkers of Disease and Drug Response. Pharmacogenomics, 12, 235-249.
https://doi.org/10.2217/pgs.10.184
|
[61]
|
Mah, J.T., Low, E.S. and Lee, E. (2011) In Silico SNP Analysis and Bioinformatics Tools: A Review of the State of the Art to Aid Drug Discovery. Drug Discovery Today, 16, 800-809. https://doi.org/10.1016/j.drudis.2011.07.005
|
[62]
|
Liu, Y., Wang, L., Kikuiri, T., Akiyama, K., Chen, C., Xu, X. and Shi, S. (2020) Mesenchymal Stem Cell-Based Tissue Regeneration Is Governed by Recipient T Lymphocytes via IFN-γ and TNF-α. Nature Medicine, 24, 1434-1442.
|
[63]
|
Bhatia, S.N. and Ingber, D.E. (2014) Microfluidic Organs-on-Chips. Nature Biotechnology, 32, 760-772. https://doi.org/10.1038/nbt.2989
|
[64]
|
Murphy, S.V. and Atala, A. (2017) 3D Bioprinting of Tissues and Organs. Nature Biotechnology, 35, 213-222.
|
[65]
|
Clevers, H. (2016) Modeling Development and Disease with Organoids. Cell, 165, 1586-1597. https://doi.org/10.1016/j.cell.2016.05.082
|
[66]
|
Abaci, H.E., Shen, Y.I. and Wu, J.C. (2015) In Vivo Imaging of Embryonic Stem Cells Reveals Patterns of Survival and Immune Rejection Following Transplantation. Stem Cells and Development, 24, 321-330.
|
[67]
|
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K. and Yamanaka, S. (2007) Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. Cell, 131, 861-872.
https://doi.org/10.1016/j.cell.2007.11.019
|
[68]
|
Walters, W.P. and Murcko, M.A. (2002) Prediction of “Drug-Likeness”. Advanced Drug Delivery Reviews, 54, 255-271.
https://doi.org/10.1016/S0169-409X(02)00003-0
|
[69]
|
Lavecchia, A. and Di Giovanni, C. (2013) Virtual Screening Strategies in Drug Discovery: A Critical Review. Current Medicinal Chemistry, 20, 2839-2860.
https://doi.org/10.2174/09298673113209990001
|
[70]
|
Cheng, F., Li, W., Wu, Z., Wang, X., Zhang, C., Li, J. and Tang, Y. (2013) Prediction of Polypharmacological Profiles of Drugs by the Integration of Chemical, Side Effect, and Therapeutic Space. Journal of Chemical Information and Modeling, 53, 753-762. https://doi.org/10.1021/ci400010x
|
[71]
|
Kitchen, D.B., Decornez, H., Furr, J.R. and Bajorath, J. (2004) Docking and Scoring in Virtual Screening for Drug Discovery: Methods and Applications. Nature Reviews Drug Discovery, 3, 935-949. https://doi.org/10.1038/nrd1549
|
[72]
|
Smith, A., Ammar, R., Nislow, C., Giaever, G. (2010) A Survey of Yeast Genomic Assays for Drug and Target Discovery. Pharmacology & Therapeutics, 127, 156-164. https://doi.org/10.1016/j.pharmthera.2010.04.012
|
[73]
|
Nermin, P.K., Murodzhon, A. and Murat, C. (2014) A Drug Similarity Network for Understanding Drug Mechanism of Action. Journal of Bioinformatics and Computational Biology, 12, Article ID: 1441007.
https://doi.org/10.1142/S0219720014410078
|
[74]
|
Yan, X., Liao, C., Liu, Z., Hagler, A.T., Gu, Q. and Xu, J. (2015) Chemical Structure Similarity Search for Ligand-Based Virtual Screening: Methods and Computational Resources. Current Drug Targets, 16, 1580-1585.
|
[75]
|
Maggiora, G., Vogt, M., Stumpfe, D. and Bajorath, J. (2014) Molecular Similarity in Medicinal Chemistry. Journal of Medicinal Chemistry, 57, 3186-3204.
https://doi.org/10.1021/jm401411z
|
[76]
|
Faulon, J.L. and Bender, A. (2010) Handbook of Chemoinformatics Algorithms. CRC Press, Boca Raton. https://doi.org/10.1201/9781420082999
|
[77]
|
Lee, K. (2010) Statistical Bioinformatics: A Guide for Life and Biomedical Science Researchers. Wiley-Blackwell, Hoboken.
|
[78]
|
Devinyak, O., Havrylyuk, D. and Lesyk, R. (2014) 3D-MoRSE Descriptors Explained. Journal of Molecular Graphics and Modelling, 54, 194-203.
https://doi.org/10.1016/j.jmgm.2014.10.006
|
[79]
|
Holzinger, A., Keiblinger, K., Holub, P., Zatloukal, K. and Müller, H. (2023) AI for Life: Trends in Artificial Intelligence for Biotechnology. New Biotechnology, 74, 16-24. https://doi.org/10.1016/j.nbt.2023.02.001
|
[80]
|
Suleiman, T.A., Tolulope, A.M., Wuraola, F.O., Olorunfemi, R., Kasali, W.A., Okorocha, B.O., Dirisu, C. and Njoku, P.C. (2023) Overview of Cancer Management—The Role of Medical Imaging and Machine Learning Techniques in Early Detection of Cancer: Prospects, Challenges, and Future Directions. Open Access Library Journal, 10, e10014. https://doi.org/10.4236/oalib.1110014
|
[81]
|
Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R.K. and Kumar, P. (2021) Artificial Intelligence to Deep Learning: Machine Intelligence Approach for Drug Discovery. Molecular Diversity, 25, 1315-1360.
https://doi.org/10.1007/s11030-021-10217-3
|
[82]
|
Saldívar-González, F.I., Aldas-Bulos, V.D., Medina-Franco, J.L. and Plisson, F. (2022) Natural Product Drug Discovery in the Artificial Intelligence Era. Chemical Science, 13, 1526-1546. https://doi.org/10.1039/D1SC04471K
|
[83]
|
Tripathi, A., Misra, K., Dhanuka, R. and Singh, J.P. (2022) Artificial Intelligence in Accelerating Drug Discovery and Development. Recent Patents on Biotechnology, 17, 9-23. https://doi.org/10.2174/1872208316666220802151129
|